NCT03588650View on ClinicalTrials.gov

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

June 28, 2021

Study Completion Date

June 28, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

HLX20

a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein

Trial Locations (6)

2010

Kinghorn cancer centre, Darlinghurst

2109

Macquarie University, Darlinghurst

3144

Cabrini Hospital, Melbourne

4000

Sunshine Coast University Hospital, Brisbane

4215

Gold Coast Hospital, Southport

5000

CMAX Clinical research, Adelaide

All Listed Sponsors

lead

Shanghai Henlius Biotech

INDUSTRY

NCT03588650 - A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter